Follow-The-Filings

Security · featured owners

TRVI Trevi Therapeutics Inc.

COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 0.5%
  • $35M
  • 2 reduce

Who owns this now

Largest portfolio weights among featured holders · max 0.5% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman reduce 0.52%
  2. Andreas Halvorsen reduce 0.08%
  3. David Witzke 0.02%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Andreas Halvorsen - Viking Global Investors 2026 Q2 0.08% Reduce −51.7% 1,544,644 $29M history
James Silverman - Opaleye Management 2026 Q2 0.52% Reduce −10.2% 310,000 $6M history
David Witzke - Avidity Partners Management 2026 Q2 0.02% Hold 6,660 $124K history

3 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Net income -$29.06M -$47.91M -$42.76M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $87.55M $109.43M $191.66M
Total non-current assets * $1.86M $1.47M $1.78M
Total assets $89.4M $110.9M $193.44M
Total current liabilities $5.82M $10.51M $9.75M
Total non-current liabilities * $1.03M $747,000 $446,000
Total equity $82.55M $99.64M $183.24M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$31.71M -$38.26M -$42.09M
Cash from investing $59.43M -$21.53M -$94.11M
Cash from financing -$7.91M $61.48M $121.01M
Net change in cash $19.81M $1.7M -$15.18M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders